| Trial | Treatments | Patients | Method |
|---|
| DeFronzo, 2009 | saxagliptin (2.5, 5, or 10 mg once daily) (n=191) vs. placebo (n=179) | Patients With Inadequately Controlled
Type 2 Diabetes With Metformin Alone | Sample size: 191/179 Primary endpoint: FU duration: 24 weeks |
| saxgliptin, renal study | saxagliptin (n=-9) vs. placebo added to patients’ current diabetes treatment (n=-9) | patients with moderate to severe renal impairment or end-stage renal disease | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks |
| saxagliptin | saxagliptin (n=-9) vs. titrated glipizide plus metformin (n=-9) | adult patients with type 2 diabetes and inadequate glycemic control | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 52 weeks |
| saxagliptin vs sitagliptin | saxagliptin 5 mg once daily add on metformin (n=403) vs. sitagliptin 100 mg onece daily add on metformin (n=398) | adults with type 2 diabetes who did not attain adequate glycemic control on metformin therapy alone | Parallel groups Sample size: 403/398 Primary endpoint: FU duration: 18 weeks |
| Rosenstock, 2008 | saxagliptin 2.5, 5, 10, 20 or 40 mg once daily (n=-9) vs. placebo (n=-9) | drug-naive patients with T2DM and inadequate glycaemic control | Sample size: -9/-9 Primary endpoint: FU duration: 12 weeks |
| CV181-011 | oral saxagliptin 2.5, 5, or 10 mg once daily (n=-9) vs. placebo (n=-9) treatment-naïve patients with type 2 diabetes | | Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| CV181-038 | Saxagliptin monotherapy (n=-9) vs. placebo (n=-9) | type 2 diabetic subjects who are not controlled with diet and exercise | Sample size: -9/-9 Primary endpoint: FU duration: |
| Jadzinsky, 2009 | saxagliptin (n=-9) vs. placebo (n=-9) | treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycaemic control | Sample size: -9/-9 Primary endpoint: FU duration: |
| CV181-057 | Saxagliptin, 5 mg (n=-9) vs. placebo (on top insulin) (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin | Sample size: -9/-9 Primary endpoint: FU duration: |
| CV181-066 | Saxagliptin (n=-9) vs. placebo (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet And Exercise And A Stable Dose Of Metformin ¡Ý1500 mg/Day | Sample size: -9/-9 Primary endpoint: FU duration: |
| CV181-080 | 2.5 mg Saxagliptin, Twice Daily (n=-9) vs. placebo (n=-9) | Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone | Sample size: -9/-9 Primary endpoint: FU duration: |
| CV181-085 | Saxagliptin in Combination With Metformin XR 1500 mg (n=-9) vs. Up-titrated Metformin XR to 2000 mg (n=-9) | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg | Sample size: -9/-9 Primary endpoint: FU duration: |
| Hollander | saxagliptin (2.5 or 5 mg) (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes and inadequate control on thiazolidinedione alone | Sample size: -9/-9 Primary endpoint: FU duration: |
| CV181-040 | saxagliptin added to a submaximal sulphonylurea dose (n=-9) vs. uptitration of sulphonylurea monotherapy (n=-9) | patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy | Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| CV181-041 | Saxagliptin (n=-9) vs. placebo (n=-9) | Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Sample size: -9/-9 Primary endpoint: FU duration: |
| Kawamori, 2012 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Forst, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Fonseca, 2012 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| SAVOR-TIMI 53, 2013 | Saxagliptin 5 mg or 2.5 mg once daily
(n=16500) vs. Placebo (n=0) | Patients With Type 2 Diabetes | Parallel groups Sample size: 16500/0 Primary endpoint: cardiovascular death, MI, ischaemic stroke, FU duration: |
| Nowicki, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Yang, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Nowicki, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Göke, 2010 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Scheen , 2010 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Stenlöf , 2010 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| SAVOR TIMI, 2013 | saxagliptin (n=8280) vs. placebo (n=8212) | patients with type 2 diabetes who had a history of,
or were at risk for, cardiovascular events | double-blind Parallel groups Sample size: 8280/8212 Primary endpoint: cardiovascular death, myocardial infarction, or ischemic stroke FU duration: 2.1 years (median) |
